Clinical Trial Update: Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging study evaluating the efficacy, safety, and tolerability of PF-06700841 topical cream in psoriasis has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• PF-06700841 topical cream (PF-06700841)

Snippet

Sponsor: Pfizer | Conditions: Psoriasis | Phase 2 | Status: COMPLETED | Results posted: 2022-06-29